Japanese journal of clinical oncology · 2026
Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikehata Yoshinori, Nishiyama Naotaka, Miyake Makito, Nishimura Nobutaka, Yuki Kita, Shimura Soichiro, Inoue Yuta, Matsumoto Takashi, Yajima Shugo, Nagumo Yoshiyuki, Morizane Shuichi, Sato Takuma, Fujii Masato, Sazuka Tomokazu, Hatakeyama Shingo, Hashine Katsuyoshi, Yamagishi Atsushi, Taoka Rikiya, Matsui Yoshiyuki, Fujimoto Kiyohide, Nishiyama Hiroyuki, Mori Keiichiro, Kimura Takahiro, Kitamura Hiroshi, Japanese Urological Oncology Group
Аннотация
BACKGROUND: The prognostic significance of non-muscle-invasive bladder cancer (NMIBC) recurrence after a prolonged disease-free interval following intravesical Bacillus Calmette-Guérin (BCG) therapy remains unclear. This multicenter study evaluated the impact of late recurrence after BCG therapy on oncological outcomes.
METHODS: This retrospective multicenter study used the Japan Urological Oncology Group database. Among 3226 patients treated with intravesical BCG for NMIBC, 238 with non-muscle-invasive intravesical recurrence ≥1 year after initial BCG therapy were analyzed, after excluding those with muscle-invasive recurrence at first recurrence. Patients were stratified by time to recurrence: 1-2 years and ≥ 2 years. Progression-free survival (PFS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier and Cox proportional hazards analyses.
RESULTS: During a median follow-up of 72.7 months, the 5-year PFS and CSS rates were 90.8% and 91.5%, respectively. PFS did not differ significantly between the 1-2-year and ≥ 2-year recurrence groups (log-rank p = 0.300). In contrast, recurrence ≥2 years was associated with significantly worse CSS than recurrence at 1-2 years (log-rank P = .018) and was a significant predictor of worse CSS in univariate analysis (hazard ratio, 8.06; 95% confidence interval, 1.02-62.6; P = .047). Repeat BCG therapy did not significantly improve PFS or CSS in patients with recurrence ≥2 years.
CONCLUSIONS: NMIBC recurrence occurring ≥2 years after initial BCG therapy may be associated with poorer cancer-specific survival despite similar progression-free survival. Late recurrence should not automatically be considered a favorable prognostic subgroup, and careful surveillance and risk stratification are warranted.
METHODS: This retrospective multicenter study used the Japan Urological Oncology Group database. Among 3226 patients treated with intravesical BCG for NMIBC, 238 with non-muscle-invasive intravesical recurrence ≥1 year after initial BCG therapy were analyzed, after excluding those with muscle-invasive recurrence at first recurrence. Patients were stratified by time to recurrence: 1-2 years and ≥ 2 years. Progression-free survival (PFS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier and Cox proportional hazards analyses.
RESULTS: During a median follow-up of 72.7 months, the 5-year PFS and CSS rates were 90.8% and 91.5%, respectively. PFS did not differ significantly between the 1-2-year and ≥ 2-year recurrence groups (log-rank p = 0.300). In contrast, recurrence ≥2 years was associated with significantly worse CSS than recurrence at 1-2 years (log-rank P = .018) and was a significant predictor of worse CSS in univariate analysis (hazard ratio, 8.06; 95% confidence interval, 1.02-62.6; P = .047). Repeat BCG therapy did not significantly improve PFS or CSS in patients with recurrence ≥2 years.
CONCLUSIONS: NMIBC recurrence occurring ≥2 years after initial BCG therapy may be associated with poorer cancer-specific survival despite similar progression-free survival. Late recurrence should not automatically be considered a favorable prognostic subgroup, and careful surveillance and risk stratification are warranted.